OP

Orsolya Papp

Product Owner at Turbine

Orsolya Papp has a diverse work experience in various organizations. Orsolya is currently working at Turbine as a Product Owner, where they started in January 2022. In addition, they hold the position of Translational Team Lead at Turbine since April 2019 and also worked as a Computational Biologist from June 2018.

Prior to working at Turbine, Orsolya worked at Semmelweis University starting in September 2015. Orsolya held a role in the 2nd Department of Pathology.

Orsolya's earliest work experience can be traced back to their time at the University of Debrecen (UD) starting in 2011. Orsolya worked in the Faculty of Public Health (Division of Biomarker Analysis) from an unspecified start date until 2015. Additionally, they had a short stint in the Faculty of Medicine (Division of Clinical Physiology) from November 2013 to December 2013.

Orsolya Papp pursued their education in a chronological order as follows:

From 2009 to 2013, they attended Debreceni Egyetem and completed their Bachelor of Applied Science (BASc) in Clinical/Medical Laboratory Science/Research and Allied Professions.

Subsequently, between 2013 and 2015, they furthered their studies at Debreceni Egyetem and obtained a Master's degree in Molecular Biology.

Following that, Orsolya enrolled at Semmelweis University, Doctoral School of Pathological Sciences from 2015 to 2018, focusing on Oncology and Cancer Biology. The details of their degree are unavailable.

In terms of additional certifications, they became a Certified Scrum Product Owner® (CSPO®) from Scrum Alliance in December 2021.

Location

Csömör, Hungary

Links


Org chart

No direct reports

Teams


Offices


Turbine

5 followers

Turbine builds a platform to understand the inner mechanisms of cancer, enabling the discovery of novel protein targets, precision biomarkers, and better translation to patients. Turbine uses its proprietary Simulated Cell technology in combination with Artificial Intelligence to build a faster and deeper biological understanding of therapeutictargets or indications, untangling the complexity of cancer.


Headquarters

Budapest, Hungary

Employees

51-200

Links